Accuray (NSDQ:ARAY) shares are down nearly 10% today as investors react to wider 3rd-quarter losses and a lower sales forecast for the rest of fiscal 2012.
The Sunnyvale, Calif.-based radiosurgery device maker reported losses of $14.9 million, or 21¢ per share, on sales of $101.8 million during the 3 months ended March 31.
Although that’s a whopping 86.0% addition to the top line, compared with Q3 2011, losses grew by some 1,183%. Excluding 1-time items, however, adjusted losses per share were 13¢, well ahead of analysts’ predictions of 21¢ apiece.
Shares of ARAY, which makes the CyberKnife radiosurgery device, were trading at $6.46 as of about 2:40 p.m., down 9.5% on the day.
"We continue to see healthy growth in our installed base, which has grown 14 percent year on year. This growth in turn drives our service revenues, which have increased 19 percent over the same period last year," president & CEO Euan Thomson said in prepared remarks. "In addition, our service gross margin continues to improve, reaching 16 percent in the third quarter which puts us well ahead of our 10 percent target for fiscal year 2012."
Accuray said it expects to post sales of $409 million to $424 million for fiscal 2012, down from prior guidance of $411 million to $426 million.
Q1 sales, earnings up for Henry Schein
First-quarter sales and earnings both rose for Henry Schein (NSDQ:HSIC).
The Melville, N.Y.-based company posted profits of $80.8 million, or 89¢ per diluted share, on sales of $2.10 billion for the 3 months ended March 31.
That compares with profits of $76.5 million, or 82¢ per diluted share, on sales of $1.95 billion during the same period last year.
Read more
LeMaitre Vascular’s Q1 profits soar
LeMaitre Vascular (NSDQ:LMAT) saw its 1st-quarter profits soar some 503% despite a 4.6% top-line slide.
The Burlington, Mass.-based firm posted profits of $386,000, or 2¢ per diluted share, on sales of $13.9 million for the 3 months ended March 31.
That compares with profits of $64,000, or 0¢ per diluted share, on sales of $14.6 million during the same period last year.
Read more
Mindray’s Q1 profits slide despite double-digit sales boost
Mindray‘s (NYSE:MR) 1st-quarter profits slid 2.9% despite a 21.1% addition to its top line.
The Shenzhen, China-based company posted profits of $36.6 million, or 31¢ per diluted share, on sales of $219.0 million for the 3 months ended March 31.
That compares with profits of $37.7 million, or 32¢ per diluted share, on sales of $180.9 million during the same period last year.
Read more
Stereotaxis boosts Q1 sales, slashes losses
Stereotaxis (NSDQ:STXS) slashed its losses by nearly 40% and added 20.1% to the top line during the 1st quarter.
The St. Louis-based firm posted losses of $5.8 million, or 11¢ per diluted share, on sales of $12.3 million for the 3 months ended March 31.
That compares with losses of $9.5 million, or 17¢ per diluted share, on sales of $10.2 million during the same period last year.
Read more
Steris profits spike in 2011
Steris (NYSE:STE) saw its profits spike 165.5% last year on 6.2% sales growth.
The Mentor, Ohio-based company posted profits of $136.1 million, or $2.31 per diluted share, on sales of $1.39 billion for the 3 months ended March 31.
That compares with profits of $51.3 million, or 85¢ per diluted share, on sales of $1.31 billion during the same period last year.
Read more
Symmetry Medical’s Q1 bottom line plunges
Symmetry Medical’s (NYSE:SMA) 1st-quarter profits plunged 39.1% despite 5.1% sales growth.
The Warsaw, Ind.-based firm posted profits of $830,000, or 2¢ per diluted share, on sales of $100.7 million for the 3 months ended March 31.
That compares with profits of $1.4 million, or 4¢ per diluted share, on sales of $95.8 million during the same period last year.
Read more
Syneron boosts Q1 sales, losses widen
Syneron Medical Ltd. (NSDQ:ELOS) boosted its 1st-quarter sales by 25.9% but saw losses widen by 10%.
The Yokneam, Israel-based company posted losses of $2.6 million, or 7¢ per diluted share, on sales of $62.7 million for the 3 months ended March 31.
That compares with losses of $2.4 million, or also 7¢ per diluted share, on sales of $49.8 million during the same period last year.
Read more
